Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2010, Article ID 470468, 7 pages
http://dx.doi.org/10.1155/2010/470468
Review Article

SOCS1, a Negative Regulator of Cytokine Signals and TLR Responses, in Human Liver Diseases

Laboratory for Immune Signal, National Institute of Biomedical Innovation, 7-6-8 Saitoasagi, Ibaraki, Osaka 567-0085, Japan

Received 22 April 2010; Accepted 10 August 2010

Academic Editor: Ekihiro Seki

Copyright © 2010 Minoru Fujimoto and Tetsuji Naka. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Fujimoto and T. Naka, “Regulation of cytokine signaling by SOCS family molecules,” Trends in Immunology, vol. 24, no. 12, pp. 659–666, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Yoshimura, T. Naka, and M. Kubo, “SOCS proteins, cytokine signalling and immune regulation,” Nature Reviews Immunology, vol. 7, no. 6, pp. 454–465, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Naka, M. Fujimoto, H. Tsutsui, and A. Yoshimura, “Negative regulation of cytokine and TLR signalings by SOCS and others,” Advances in Immunology, vol. 87, pp. 61–122, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. D. C. Palmer and N. P. Restifo, “Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function,” Trends in Immunology, vol. 30, no. 12, pp. 592–602, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. S. L. Cassel and P. B. Rothman, “Chapter 3: role of SOCS in allergic and innate immune responses,” Advances in Immunology, vol. 103, pp. 49–76, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Mostecki, B. M. Showalter, and P. B. Rothman, “Early growth response-1 regulates lipopolysaccharide-induced suppressor of cytokine signaling-1 transcription,” The Journal of Biological Chemistry, vol. 280, no. 4, pp. 2596–2605, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Nakagawa, T. Naka, H. Tsutsui et al., “SOCS-1 participates in negative regulation of LPS responses,” Immunity, vol. 17, no. 5, pp. 677–687, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. I. Kinjyo, T. Hanada, K. Inagaki-Ohara et al., “SOCS1/JAB is a negative regulator of LPS-induced macrophage activation,” Immunity, vol. 17, no. 5, pp. 583–591, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Baetz, M. Frey, K. Heeg, and A. H. Dalpke, “Suppressor of cytokine signaling (SOCS) proteins indirectly regulate Toll-like receptor signaling in innate immune cells,” The Journal of Biological Chemistry, vol. 279, no. 52, pp. 54708–54715, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Gingras, E. Parganas, A. De Pauw, J. N. Ihle, and P. J. Murray, “Re-examination of the role of suppressor of cytokine signaling 1 (SOCS1) in the regulation of Toll-like receptor signaling,” The Journal of Biological Chemistry, vol. 279, no. 52, pp. 54702–54707, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. C. M. Prêle, E. A. Woodward, J. Bisley, A. Keith-Magee, S. E. Nicholson, and P. H. Hart, “SOCS1 regulates the IFN but not NFkappaB pathway in TLR-stimulated human monocytes and macrophages,” The Journal of Immunology, vol. 181, no. 11, pp. 8018–8026, 2008. View at Google Scholar · View at Scopus
  12. J. E. Fenner, R. Starr, A. L. Cornish et al., “Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity,” Nature Immunology, vol. 7, no. 1, pp. 33–39, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Mansell, R. Smith, S. L. Doyle et al., “Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation,” Nature Immunology, vol. 7, no. 2, pp. 148–155, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. M. J. Scott, S. Liu, R. A. Shapiro, Y. Vodovotz, and T. R. Billiar, “Endotoxin uptake in mouse liver is blocked by endotoxin pretreatment through a suppressor of cytokine signaling-1-dependent mechanism,” Hepatology, vol. 49, no. 5, pp. 1695–1708, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Ryo, F. Suizu, Y. Yoshida et al., “Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA,” Molecular Cell, vol. 12, no. 6, pp. 1413–1426, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Okugawa, Y. Ota, T. Kitazawa et al., “Janus kinase 2 is involved in lipopolysaccharide-induced activation of macrophages,” American Journal of Physiology, vol. 285, no. 2, pp. C399–C408, 2003. View at Google Scholar · View at Scopus
  17. A. Kimura, T. Naka, T. Muta et al., “Suppressor of cytokine signaling-1 selectively inhibits LPS-induced IL-6 production by regulating JAK-STAT,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 47, pp. 17089–17094, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Naka, H. Tsutsui, M. Fujimoto et al., “SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-γ and IL-4 signaling in vivo,” Immunity, vol. 14, no. 5, pp. 535–545, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. W. S. Alexander, R. Starr, J. E. Fenner et al., “SOCS1 is a critical inhibitor of interferon γ signaling and prevents the potentially fatal neonatal actions of this cytokine,” Cell, vol. 98, no. 5, pp. 597–608, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Hong, B. Jaruga, W. H. Kim et al., “Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS,” Journal of Clinical Investigation, vol. 110, no. 10, pp. 1503–1513, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. B. A. Croker, D. L. Krebs, J.-G. Zhang et al., “SOCS3 negatively regulates IL-6 signaling in vivo,” Nature Immunology, vol. 4, no. 6, pp. 540–545, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Torisu, M. Nakaya, S. Watanabe et al., “Suppressor of cytokine signaling 1 protects mice against concanavalin A-induced hepatitis by inhibiting apoptosis,” Hepatology, vol. 47, no. 5, pp. 1644–1654, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Ogata, T. Kobayashi, T. Chinen et al., “Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis,” Gastroenterology, vol. 131, no. 1, pp. 179–193, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Yoshida, H. Ogata, M. Kamio et al., “SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis,” Journal of Experimental Medicine, vol. 199, no. 12, pp. 1701–1707, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Seki, H. Tsutsui, Y. Iimuro et al., “Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration,” Hepatology, vol. 41, no. 3, pp. 443–450, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. J. S. Campbell, K. J. Riehle, J. T. Brooling, R. L. Bauer, C. Mitchell, and N. Fausto, “Proinflammatory cytokine production in liver regeneration is Myd88-dependent, but independent of Cd14, Tlr2, and Tlr4,” The Journal of Immunology, vol. 176, no. 4, pp. 2522–2528, 2006. View at Google Scholar · View at Scopus
  27. J. S. Campbell, L. Prichard, F. Schaper et al., “Expression of suppressors of cytokine signaling during liver regeneration,” Journal of Clinical Investigation, vol. 107, no. 10, pp. 1285–1292, 2001. View at Google Scholar · View at Scopus
  28. S. Brand, J. Dambacher, F. Beigel et al., “IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro,” American Journal of Physiology, vol. 292, no. 4, pp. G1019–G1028, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Seki, Y. Kondo, Y. Iimuro et al., “Demonstration of cooperative contribution of MET- and EGFR-mediated STAT3 phosphorylation to liver regeneration by exogenous suppressor of cytokine signalings,” Journal of Hepatology, vol. 48, no. 2, pp. 237–245, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. K. J. Riehle, J. S. Campbell, R. S. McMahan et al., “Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3,” Journal of Experimental Medicine, vol. 205, no. 1, pp. 91–103, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Lebrun and E. Van Obberghen, “SOCS proteins causing trouble in insulin action,” Acta Physiologica, vol. 192, no. 1, pp. 29–36, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Ueki, T. Kondo, Y.-H. Tseng, and C. R. Kahn, “Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 28, pp. 10422–10427, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Kawazoe, T. Naka, M. Fujimoto et al., “Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation,” Journal of Experimental Medicine, vol. 193, no. 2, pp. 263–269, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Shi, I. Tzameli, C. Bjørbæk, and J. S. Flier, “Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling,” The Journal of Biological Chemistry, vol. 279, no. 33, pp. 34733–34740, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Torisu, N. Sato, D. Yoshiga et al., “The dual function of hepatic SOCS3 in insulin resistance in vivo,” Genes to Cells, vol. 12, no. 2, pp. 143–154, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. A. S. Banks, J. Li, L. McKeag et al., “Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans,” Journal of Clinical Investigation, vol. 115, no. 9, pp. 2462–2471, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Yoshikawa, K. Matsubara, G.-S. Qian et al., “SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity,” Nature Genetics, vol. 28, no. 1, pp. 29–35, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Nagai, Y. S. Kim, N. Konishi et al., “Combined hypermethylation and chromosome loss associated with inactivation of SSI-1/SOCS-1/JAB gene in human hepatocellular carcinomas,” Cancer Letters, vol. 186, no. 1, pp. 59–65, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Ko, S.-J. Kim, J.-W. Joh, C.-K. Park, J. Park, and D.-H. Kim, “CpG island hypermethylation of SOCS-1 gene is inversely associated with HBV infection in hepatocellular carcinoma,” Cancer Letters, vol. 271, no. 2, pp. 240–250, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Gylvin, J. Ek, R. Nolsøe et al., “Functional SOCS1 polymorphisms are associated with variation in obesity in whites,” Diabetes, Obesity and Metabolism, vol. 11, no. 3, pp. 196–203, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. X.-P. Yang, F. Schaper, A. Teubner et al., “Interleukin-6 plays a crucial role in the hepatic expression of SOCS3 during acute inflammatory processes in vivo,” Journal of Hepatology, vol. 43, no. 4, pp. 704–710, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. X. Liu, Y. Zhang, Y. Yu, X. Yang, and X. Cao, “SOCS3 promotes TLR4 response in macrophages by feedback inhibiting TGF-β1/Smad3 signaling,” Molecular Immunology, vol. 45, no. 5, pp. 1405–1413, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Ogata, T. Chinen, T. Yoshida et al., “Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-β1 production,” Oncogene, vol. 25, no. 17, pp. 2520–2530, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. W. E. Naugler, T. Sakurai, S. Kim et al., “Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production,” Science, vol. 317, no. 5834, pp. 121–124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. E. J. Park, J. H. Lee, G.-Y. Yu et al., “Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression,” Cell, vol. 140, no. 2, pp. 197–208, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Nakaya, M. Hashimoto, and R. Nakagawaet, “SOCS3 in T and NKT cells negatively regulates cytokine production and ameliorates ConA-induced hepatitis,” The Journal of Immunology, vol. 183, no. 11, pp. 7047–7053, 2009. View at Google Scholar
  47. S. Fushimi, T. Ogino, J. Hara et al., “Forced expression of suppressor of cytokine signaling 3 in T cells protects the development of concanavalin A-induced hepatitis in mice,” Clinical Immunology, vol. 133, no. 3, pp. 437–446, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. D. Jo, D. Liu, S. Yao, R. D. Collins, and J. Hawiger, “Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis,” Nature Medicine, vol. 11, no. 8, pp. 892–898, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. B. Koeberlein, A. Z. Hausen, N. Bektas et al., “Hepatitis B virus overexpresses suppressor of cytokine signaling-3 (SOCS3) thereby contributing to severity of inflammation in the liver,” Virus Research, vol. 148, no. 1-2, pp. 51–59, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Huang, J. J. Feld, R. K. Sapp et al., “Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C,” Gastroenterology, vol. 132, no. 2, pp. 733–744, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. K. Kim, K. H. Kim, and J. Cheong, “Hepatitis B virus X protein impairs hepatic insulin signaling through degradation of IRS1 and induction of SOCS3,” PLoS One, vol. 5, no. 3, Article ID e8649, 2010. View at Google Scholar
  52. J. G. Bode, S. Ludwig, C. Ehrhardt et al., “IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3,” The FASEB Journal, vol. 17, no. 3, pp. 488–490, 2003. View at Google Scholar · View at Scopus
  53. T. Kawaguchi, T. Yoshida, M. Harada et al., “Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3,” American Journal of Pathology, vol. 165, no. 5, pp. 1499–1508, 2004. View at Google Scholar · View at Scopus
  54. H. Miyoshi, H. Fujie, Y. Shintani et al., “Hepatitis C virus core protein exerts an inhibitory effect on suppressor of cytokine signaling (SOCS)-1 gene expression,” Journal of Hepatology, vol. 43, no. 5, pp. 757–763, 2005. View at Publisher · View at Google Scholar · View at Scopus